Preventing Leg Amputations in Critical Limb Ischemia With Below-the-Knee Drug-Eluting Stents The PaRADISE (PReventing Amputations using Drug eluting StEnts) Trial by Feiring, Andrew J. et al.
C
m
e
u
o
fi
2
l
F
M
t
c
2
Journal of the American College of Cardiology Vol. 55, No. 15, 2010
© 2010 by the American College of Cardiology Foundation ISSN 0735-1097/10/$36.00
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Preventing Leg Amputations in
Critical Limb Ischemia With
Below-the-Knee Drug-Eluting Stents
The PaRADISE (PReventing Amputations using
Drug eluting StEnts) Trial
Andrew J. Feiring, MD,* Mari Krahn, RN,* Lori Nelson, NP,* Amy Wesolowski, RN,*
Daniel Eastwood, MS,† Aniko Szabo, PHD†
Milwaukee, Wisconsin
Objectives We investigated the efficacy and safety of using balloon expandable drug-eluting stents (DES) to prevent ampu-
tations in patients with below-the-knee critical limb ischemia.
Background Critical limb ischemia patients have a 1-year amputation rate of 30% and a mortality rate of 25%. Most patients
with critical limb ischemia have severe below-the-knee arterial disease that limits the use of bypass surgery or
balloon angioplasty.
Methods In all, 106 patients (118 limbs) were treated with DES in this prospective, nonrandomized trial. No patients were
excluded because of comorbidities or unfavorable anatomy. Primary end points were major amputation and
mortality, each stratified by Rutherford category.
Results The mean patient age was 74  9 years. There were 228 DES implanted (83% Cypher [Cordis, Johnson & John-
son, Warren, New Jersey], 17% Taxus [Boston Scientific, Maple Grove, Minnesota]). The number of stents per
limb was 1.9  0.9, and 35% of limbs received overlapping DES (length of 60  13 mm). There were no proce-
dural deaths, and 96% of patients were discharged within 24 h. The 3-year cumulative incidence of amputation
was 6  2%, survival was 71  5%, and amputation-free-survival was 68  5%. Only 12% of patients who died
had a preceding major amputation. Rutherford category, age, creatinine level, and dialysis (p  0.001 to 0.04)
were predictors of death but not amputation. Target limb revascularization occurred in 15% of patients, and re-
peat angiography in 35% of patients revealed a binary restenosis in 12%.
Conclusions Treating below-the-knee critical limb ischemia with DES is an effective and safe means of preventing major am-
putation and relieving symptoms. Procedural complications and limb revascularization rates were low. Limb sal-
vage and survival rates in patients treated with DES exceed those of historic controls. (J Am Coll Cardiol 2010;
55:1580–9) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.11.072g
s
c
a
t
c
a
r
t
a
britical limb ischemia (CLI) is a common and devastating
anifestation of peripheral arterial disease. The diagnosis is
stablished when patients present with ischemic rest pain,
lcerations, or gangrene of the leg associated with evidence
f reduced arterial blood flow to the foot (1). Within the
rst year of illness, 30% suffer a major amputation (MA),
5% will die, and 20% endure with unresolved pain or tissue
oss (1,2).
rom the *Division of Cardiac and Vascular Intervention, Columbia-St. Mary’s
edical Center, and the †Department of Population Health, Division of Biostatis-
ics, Medical College of Wisconsin, Milwaukee, Wisconsin. Dr. Feiring is a
onsultant for Cordis, Johnson & Johnson, Warren, New Jersey.l
Manuscript received August 10, 2009; revised manuscript received October 30,
009, accepted November 9, 2009.Preventing MA in CLI is arguably the most important
oal and is predicated on the ability to restore and maintain
traight line tibial arterial flow to the foot. Although many
onsider surgical bypass the therapeutic cornerstone, this
pproach is infrequently exercised because of poor surgical
argets, lack of suitable conduits, advanced age, and multiple
omorbidities that result in prohibitive surgical morbidity
nd mortality (1,2). Consequently, transtibial amputation
emains the most frequent treatment for CLI when pain,
issue loss, and infection become intractable (3).
The less invasive nature of percutaneous transluminal
ngioplasty (PTA) makes it an attractive alternative to
ypass surgery. However, its reliability and durability is
imited, with a 1-year primary tibial patency rate of 20% to
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April 13, 2010:1580–9 Preventing Leg Amputations With DES0% (4,5). Consequently, tissue perfusion is often inade-
uate to heal tissue loss and resolve rest pain.
The BASIL (Bypass Versus Angioplasty in Severe Ische-
ia of the Leg) study compared PTA to surgical bypass for
reating leg ischemia. After 2 years, both approaches achieved
herapeutic equipoise with regard to amputation and survival.
owever, each modality had significant limitations. At 1
onth, 20% of PTAs failed, whereas the combined mortality,
troke, and coronary event rate with surgery was 15%. Further-
ore, although the BASIL study patients were at relatively low
isk with favorable anatomy, the amputation-free survival at 1
nd 3 years was approximately 70% and 55%, respectively (6).
Previously, we demonstrated that many limitations asso-
iated with below-the-knee (BTK) PTA could be circum-
ented by using balloon expandable coronary stents (7).
evertheless, despite elimination of early interventional
ailures and hemodynamic improvement, this approach was
uboptimal because of late in-stent restenosis ranging from
0% to 60% (8,9).
With the advent of coronary artery drug-eluting stents
DES), we postulated that the logical next step was to
ncorporate this technology into an algorithm for treating
nfragenual CLI (7). Subsequently, a number of single-
enter studies have demonstrated that BTK DES is safe and
ssociated with low rates of in-stent restenosis or occlusion
8–13). To date, however, only small numbers of patients
ave been reported, and there is little long-term follow-up
vailable.
In this communication, we present the results of the
aRADISE (PReventing Amputations using Drug eluting
tEnts) trial, which represents the largest cohort and
ongest follow-up of CLI patients treated with primary
TK DES. In lieu of a control arm, the PaRADISE study
ata were compared to historic data from the TASC II
Trans-Atlantic Inter-Society Consensus II) document and
evel-1 evidence from the BASIL trial (1,6).
ethods
etween May 10, 2003, and March 1, 2009, CLI patients
ere sequentially enrolled in the institutional review board-
pproved, single-center and -operator PaRADISE trial. All
atients gave written informed consent for primary implan-
ation of the Food and Drug Administration-approved
oronary DES stents (Cypher, Cordis, Johnson & Johnson,
arren, New Jersey, or Taxus, Boston Scientific, Maple
rove, Minnesota). Critical limb ischemia was defined
ccording to the Second European Consensus Document
14). Patients were stratified according to the Rutherford-
ecker scale where categories 4, 5, and 6 corresponded to
esting pain, minor ulcerations, and gangrene, respectively
15). Patients with uninterruptible ankle-brachial indexes
i.e., incompressible vessels) were stratified according to
heir Rutherford presentation. No patients were excluded
ecause of age, renal insufficiency, dialysis, prior stroke, heart
ailure, unstable angina, cancer, or other life-limiting illnesses. wnterventional technique. We
ave previously described the
echniques for BTK stenting
7,16). The interventional objec-
ive was to establish straight-line
ow to the foot in 1 tibial vessel.
atients were enrolled when the
.014-inch wire crossed the tar-
eted BTK lesion. Lesions were
re-dilated to test lesion compli-
nce, and stents were deployed to
chieve a slight negative residual
ompared to the distal reference
essel. Technical success was de-
ned as a residual post-stent ste-
osis of 20.0%, and angiographic
uccess was defined as restitution of straight-line tibial flow to
he foot. To limit institutional costs, a goal of 2 DES per limb
as set. Long-segment disease was treated by stenting the
nflow and total occlusions lesions and treating the intervening
rterial segments with long balloon PTA (Amphirion, Invatec,
rescia, Italy).
Patients with significant above-knee lesions were con-
emporaneously treated using a variety of endovascular
echniques. Patients with SFA occlusions that could not be
ecanalized were considered candidates for tibial stenting by
he antegrade popliteal approach if the popliteal segment
as adequately collateralized (16).
harmacologic therapy. Before intervention, all patients
ere started on a regimen of aspirin 81 mg, clopidogrel 75
g daily, or ticlopidine 250 mg bid. Patients received
nfractionated heparin, 40 to 50 U/kg. Glycoprotein inhib-
tors were not routinely used. Patients with renal insuffi-
iency (creatinine 1.3 mg%) were hydrated with D5W-
odium bicarbonate (150 mEq/l) infusion continued for 12
o 24 h. After the procedure, indefinite thienopyridine,
spirin, and lipid therapy was encouraged.
linical follow-up and end points. Routine follow-up was
t 1, 3, and 6 months and every 6 months thereafter.
rimary end points were MA (amputation above the ankle),
ll-cause mortality, tissue healing, and relief of rest pain.
lanned digital or transmetatarsal amputations were not
onsidered clinical failures if the amputation healed. Deaths
ere confirmed using the Social Security Death Index, and
mputations were documented by review of hospital records
nd patient contact.
Major adverse events included stroke, myocardial infarction,
ajor infections, compartment syndrome, flow-limiting dis-
ection, distal embolization, vessel occlusion, retroperitoneal
leed, pseudoaneurysm, hematomas, and contrast nephropathy
elaying discharge or dialysis.
Repeat angiography was performed for delayed tissue
ealing, recurrent symptoms, or incidental to angiographic
valuation of other vascular territories. Repeat intervention
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
BTK  below the knee
CLI  critical limb
ischemia
DES  drug-eluting stent(s)
MA  major amputation
PTA  percutaneous
transluminal angioplasty
SFA  superficial femoral
artery
TASC  Trans-Atlantic
Inter-Society Consensusas driven by failure-to-heal ulcerations or unresolved
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Preventing Leg Amputations With DES April 13, 2010:1580–9ymptoms. Asymptomatic new lesions or in-stent restenosis
ere not pre-emptively treated.
tatistical analysis. Descriptive data are presented as the
ean  SD. Categorical and continuous outcomes were
ompared by Fisher’s exact test and Welsh’s t test, respec-
ively. All time-to-event analyses were performed on a
atient level with the outcome of the first leg treated unless
therwise specified. Kaplan-Meier survival plots were cre-
ted for overall survival and amputation-free survival. Cox
roportional hazard models for overall survival and
mputation-free survival were used to estimate the simulta-
eous effect of age, kidney function coded as creatinine
2/2/dialysis, Rutherford score, and statin use selected
or face-value validity. The functional form of the predictors
as estimated using Martingale residuals. The effect of
ther predictors was evaluated by adding them to the basic
odel one at a time.
The cumulative incidence of amputation was estimated
sing Aalen’s estimator. Because of the small number of
vents, predictors were evaluated only univariately using
ine-Gray regression of the subdistribution hazard.
Survival estimates for the BASIL study were taken from
he BASIL text when available and read from the Kaplan-
Figure 1 Patient Flow Diagram
(A) Clinical outcomes. (B) Angiographic outcomes. RS  binary restenosis; TO eier curves. The corresponding standard errors were
stimated using Peto’s formula based on the survival prob-
bility and the number at risk given at the bottom of each
gure, resulting in conservative p values. An unpooled z-test
as used to compare the survival estimates from the BASIL
tudy and the current study. Analysis was performed in SAS
ersion 9.2. (SAS Institute, Cary, North Carolina) and
2.8.1 with the cmprsk 2.2.0 package.
esults
ngiographic evaluation was performed on 118 consec-
tive patients (130 limbs). The patient flow is illustrated
n Figure 1. Twelve patients were excluded because of
ailure to cross total occlusions (6 SFA: 2 popliteal and 4
ibial). Thus, 106 patients (118 limbs) received 1 or more
ES. Patient demographics are seen in Table 1. The mean
atient age was 74  9.8 years (age range 44 to 96 years),
nd 29% were over the age of 80 years. Females were on
verage 3 years older than males (p  NS).
Patients with indeterminate ankle-brachial indexes (16%)
ere nearly equally distributed among the 3 Rutherford
cclusion.total o
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April 13, 2010:1580–9 Preventing Leg Amputations With DESategories. The contralateral retrograde approach was used
2% of the time. Contemporaneous SFA or popliteal artery
nterventions were performed in 48% of limbs. Occlusion of
ll 3 tibial vessels or jeopardized single vessel run-off was
resent in 74% of patients. Technical success in delivering
tents was 100%. Angiographic success was 96% with 5
ailures to establish continuous flow to the ankle. Examples
f tibial interventions are seen in Figures 2 and 3. A total of
28 stents were deployed, and 35% of patients received
verlapping stents (mean length of 60  13 mm) (Table 2).
Clinical follow-up was 100%, and the mean length of
ollow-up was 27.4  18.6 months (range 2.4 to 69
onths). Outcomes are seen in Table 3. There was 1 major
dverse event (failure to maintain SFA patency resulting in
MA). In the first year, there were 6 MAs and none
hereafter. Rest pain was relieved in 93% of patients, and all
ut 1 of 10 planned minor amputations healed (Table 3).
wo additional patients underwent late femoral-popliteal
ypass. In these cases, femoral-tibial bypass was avoided
ecause of DES-maintained tibial outflow. The mean
ength of hospital stay was 1.2 days. Contrast nephropathy
ccurred in 4 patients, although none required dialysis.
The cumulative incidence of amputation at 3 years was
 2% (Fig. 4A). Among patients alive at 3 years, 96%
ere without a MA, and among those who died, 88% did
ot have a MA. Cumulative incidence of amputation curves
tratified by Rutherford category is seen in Figure 4B.
utherford 4 and 5 patients had a nonsignificant trend in
atient CharacteristicsTable 1 Patient Characteristics
Male (%) Female (%) p Value
n 72 34 0.003
Age at entry, yrs 73.8 10 76.0 8 0.24
Diabetes mellitus 35 (49) 15 (44) 0.68
Creatinine, mg%* 1.6 0.7 1.4 1.0 0.41
eGFR, ml/min/1.73 m2 53 23 51 32 0.80
Lipid therapy 56 (79) 26 (76) 0.80
Coronary artery disease 41 (59) 16 (44) 0.21
Tobacco 27 (38) 8 (22) 0.13
Dialysis 1 (1) 3 (9) 0.10
Died 17 (24) 8 (23) 1.00
Age at death, yrs 80 8.5 77 7.9 0.31
Died without major amputation 16/17 (94) 6/8 (75) 0.23
Age at last follow-up of living, yrs 75 10 78.9 8.7 0.06
Limbs treated 80 38
Rutherford-Becker category
4 31 (39) 14 (37) 0.83
5 24 (30) 12 (31.5) 1.0
6 25 (31) 12 (31.5) 1.0
Tibial run-off, patent vessels 1.0 0.8 0.8 0.8 0.89
Above-knee intervention 35 (44) 21 (55) 0.32
Major amputations 2 (3) 4 (11) 0.07
Minor amputations 6 (8) 4 (11) 0.74
alues are n, mean  SD, or n (%). *Excluding patients on dialysis.
eGFR  estimated glomerular filtration rate.avor of improved limb survival compared with category 6 patients. None of the clinical covariates was a significant
redictor of MA (Table 4).
During follow-up, 25 patients died, with a mean survival
f 12.8  9.2 months (range 1.5 to 36 months) after the
rocedure. The Kaplan-Meier survival curves with and
ithout stratification by Rutherford category are depicted in
igures 5A and 5B. Survival at 3 years was 71  5%. Cox
ultivariable analysis identified entry age, creatinine/
ialysis, and Rutherford category (4 or 5 vs. 6) as positive
redictors of mortality (Table 5). The PaRADISE study
mputation-free survival versus the BASIL trial results
re compared in Figure 6. In nearly all cases, DES
atients fared statistically better than either surgery or
TA patients, with the exception of bypass surgery at the
hird year (Table 6).
Repeat angiographic evaluation was performed in 38
atients (Fig. 1B): 18 were evaluated for recurrent ipsi-
ateral symptoms, and 20 asymptomatic patients under-
ent angiography incidental to other vascular procedures.
hus, 36% of patients and 33% of the DES-implanted
atients underwent angiographic evaluation at a mean
nterval of 256  244 days after the initial procedure.
tent failure (binary restenosis or occlusion) was present
n 24% of patients who presented with symptoms,
hereas two-thirds of these patients had progressive
isease involving the SFA or popliteal arteries. In these
atients, 6 additional DES were placed at sites of
revious intervention and 11 were placed at sites remote
rom the initial intervention. Four patients who had
epeat interventions subsequently underwent BTK am-
utations. For asymptomatic patients (20 limbs, 45 at-
isk stents), stent failure was 4%. Overall restenosis and
cclusion were statistically less with the Cypher stent
han with the Taxus stent (p  0.003).
iscussion
he unique observations of the PaRADISE trial can be
ummarized as follows. 1) CLI patients treated with DES
ad a 3-year limb salvage of 94%, which significantly
xceeds historical expectations for either PTA or bypass
urgery. 2) A strategy of primary DES for BTK-CLI is
afe and minimizes early procedural morbidity and mor-
ality. 3) A DES for CLI is durable. Stent failures were
ew, and the need for repeat intervention was low.
ound healing and relief of resting pain were demon-
trated in 93% of patients. 4) Compared with historic
ontrols, mortality may be favorably influenced by a
ES-centered strategy.
ajor leg amputations and the PaRADISE study. The
aRADISE study 1- and 3-year freedom from MA was 96%
nd 94% respectively. Only 12% of patients who died had a
A. There was a nonsignificant trend favoring improved limb
alvage in Rutherford 4 and 5 patients versus Rutherford 6,
7% vs. 88% (Fig. 4B). This observation is reasonable since
atients with extensive tissue loss are less likely to heal even
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Preventing Leg Amputations With DES April 13, 2010:1580–9ith optimal revascularization. These data suggest that more
imely referral of CLI patients for endovascular-based DES
herapy might further reduce amputations.
The TASC II benchmarks a 1-year MA rate of 30% with an
dditional 20% who fail to resolve their symptoms, whereas the
aRADISE study patients had a 6% 3-year amputation rate,
nd symptoms resolved in 99% of unamputated limbs. The 1-
Figure 2 Bare-Metal In-Stent Restenosis Successfully Treated
(A) An 87-year-old patient, Rutherford 5 critical limb ischemia (CLI). The arrow ind
(BMS) and 2 overlapping 3.5-mm Cypher drug-eluting stents (DES). (C) The patien
brackets) and the patent DES (solid brackets). (D) Incidental angiography 18 mond 3-year amputation rate in the BASIL study were surpris- tngly low at 11% and 18%. However, comparing the BASIL
tudy to the PaRADISE study is problematic because of
ifferences in study design and data reportage. The BASIL
tudy patients were a selected low-risk cohort. Nearly 90% of
atients screened were excluded for unsuitable anatomy or
omorbidities precluding surgery. Additionally, 25% of pa-
ients had true CLI. Furthermore, only one-third underwent
DES
popliteal artery occlusion. (B) After placing a proximal 4.0 mm bare-metal stent
ed 17 months later with rest pain. Note in-stent restenosis of the BMS (dotted
fter treating in-stent restenosis with a 3.5-mm  23-mm Cypher stent.With
icates
t return
nths aibial bypass, underscoring the low-risk nature of these pa-
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April 13, 2010:1580–9 Preventing Leg Amputations With DESients. Consequently, the BASIL study cohort was composed
f low-risk patients with the most favorable arterial anatomy.
In contrast, the PaRADISE study patients were not
xcluded for comorbidities, and they had more challenging
Figure 3 Demonstration of the Technical Ease With Which DES
(A) A 68-year-old patient with Rutherford 6 critical limb ischemia (CLI) 1 year after
(B) The solid arrow points to bypass graft insertion proximal to posterior tibial
drug-eluting stent (DES) in challenging anatomy from the retrograde contralateral a
(D) Completion angiogram. (E) Angiography 4 years after initial implant. (F) Clinica
rug-Eluting Stent CharacteristicsTable 2 Drug-Eluting Stent Characteristics
Stent n (%)
Cypher* 188 (83)
Taxus† 40 (17)
Stents per limb (range) 1.9 0.9 (1–5)
Single stent length, mm 26.9 5.8 (8–33)
Mode 28
Diameter, mm 2.9 0.4
Mode 3.0
Limbs with overlapping stents 41 (35%)
Length of overlap, mm 61 15
Range 36–99
Mode 56
Median diameter stent, mm 3.0
Angiographic restenosis/Taxus 5/40 (12.5%)
Angiographic restenosis/Cypher 4/188 (2.5%)rCordis, Johnson & Johnson; †Boston Scientific.natomy by definition as all patients had BTK intervention.
evertheless, despite these differences, at 3 years the PaRA-
ISE study maintained a 13  6.3% limb survival advan-
age over the BASIL trial.
We hypothesize that improved limb salvage was prin-
ipally related to sustained tibial artery patency resulting
rom DES implants. Although assessing stent patency
as not our primary focus, the data suggest that long-
erm patency was maintained in the overwhelming ma-
ority of patients. The flat slope of the limb survival curve
Fig. 4) suggests that the DES repair was durable.
dditionally, because 74% of patients had either single or
o tibial vessel run-off, the expected consequence of stent
ailure would be recurrence of symptoms and failure to
eal ulcerations or minor amputations. This inference is
upported by the observation that within 6 months of a
ailed surgical reconstruction, 40% of patients will un-
ergo a MA and 20% will die (17). Finally, 34% of
atients had repeat angiographic evaluation. In asymp-
omatic patients, the binary restenosis rate was 4% (2 of
5 stents), whereas in symptomatic patients, the binary
Be Delivered to Challenging Tibial Anatomy
al-posterior tibial bypass. Toe amputation (arrow) and ankle ulcer failed to heal.
; the dotted arrows note additional tibial lesions. (C) The ability to place
ch is demonstrated. The arrows trace wire course into the anterior tibial artery.
onse 3 months after intervention.Can
femor
lesion
pproa
l respestenosis rate was 24% (7 of 29 stents) (Fig. 1B). Thus,
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*Above-knee amputation.
NS  not significant; RB  Rutherford-Becker category.
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Preventing Leg Amputations With DES April 13, 2010:1580–9he combined angiographic restenosis rate was 11%,
lthough this may represent an overestimation because
early two-thirds of the asymptomatic patients did not
ndergo angiography. These data, in conjunction with
revious studies, suggest that use of DES for tibial
ntervention is safe, effective, and durable.
ortality and CLI. In the PaRADISE trial, the first- and
hird-year mortality rates were 87  4% and 71  5%,
espectively (Fig. 5A). When compared with the TASC II
tudy, the mortality in the PaRADISE study at 1 year was
ower than in the TASC II study at 3 years. When
ontrasted with the BASIL study surgical group, the mor-
ality benefit of the PaRADISE study was only apparent
uring the first year, which primarily reflects the differences
n procedural mortality (Table 6). However, unlike the
ASIL trial, the PaRADISE study patients were older
35% vs. 25% 80 years), had worse renal function (creat-
nine 1.8 mg/dl vs. 1.3 mg/dl), and included all patients
egardless of clinical status. Consequently, the survival
Clinical Status
RB 5 (%) RB 6 (%) p Value
1.1 0.6 1.2 0.9 NS
37 37
36 (97) 32 (86) 0.09
1 5
1 4 NS
0 1 NS
2 7 0.004
0 0 NS
1 2 NS
0 0 NS
0 0 NS
0 0 NS
0 0 NS
umulative Incidence of Amputation:nivariate Fi e-Gray AnalysisTable 4 Cumulative Inc dence of Amputation:Univariate Fine-Gray Analysis
Covariate p Value Hazard 95% CI
Age 0.09 0.94 0.87–1.01
Creatinine* 0.94 1.06 0.26–4.21
Dialysis 0.08 5.26 0.8–34.5
Diabetes mellitus 0.34 2.27 0.96–12.2
eGFR 0.79 0.99 0.96–1.03
Male vs. female 0.34 0.46 0.09–2.38
Rutherford 6 vs. 4 and 5 0.10 4.14 0.76–22.6
Statin 0.10 0.27 0.05–1.31
Above-knee intervention 0.96 0.96 0.19–4.72
Stents per leg 0.37 0.57 0.17–1.94
ata are depicted as 1  (cumulative incidence of amputation) for display purposes. *ExcludingClinical Outcomes After InterventionTable 3 Clinical Outcomes After Intervention
RB 4 (%)
Procedure to discharge, days 1.2 0.8
Number of limbs 44
Clinical status, n
Healed/relief of rest pain 43 (98)
Worsened 1 (2)
Major amputation 1*
Minor amputations not healed 0
Minor amputation healed 0
Procedure-related death 0
Contrast nephropathy 1
Procedure-related amputation 1
Myocardial infarction 0
Stroke 0
Infection 0Figure 4 Rate of Major Amputations in Patients
Treated With Below-the-Knee Drug-Eluting Stents
(A) 1  cumulative incidence of amputation curve and confidence limits.
(B) 1  (cumulative incidence of amputation) stratified according to entry Ruther-
ford category. atients on dialysis.
CI  confidence interval; eGFR  estimated glomerular filtration rate.
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April 13, 2010:1580–9 Preventing Leg Amputations With DESenefit in the PaRADISE study might have been greater
ad the BASIL trial included a similar patient set.
The PaRADISE study survival was independently corre-
ated with Rutherford category. At 3 years, patients in catego-
ies 4 and 5 had significantly better survival (87  6%
nd 83  13) than did patients in category 6, for whom
urvival was a dismal 43  9% (p  0.001 for category 4 and
Figure 5 All-Cause Mortality in Patients
Treated With Below-the-Knee Drug-Eluting Stents
(A) Kaplan-Meier survival curve with confidence limits. (B) Kaplan-Meier survival
curves stratified according to entry Rutherford category.
ox Analysis Overall SurvivalTable 5 Cox Analysis Overall Survival
Covariate p Value Hazard 95% CI
Age 0.03* 1.06 1.006–1.116
Creatinine 2 vs. 2 0.0013* 5.09 1.89–13.75
Dialysis vs. creatinine 2 0.11 3.26 0.75–14.01
Rutherford 6 vs. 4 and 5 0.0009* 5.35 1.98–14.44
Statin 0.04* 0.36 0.14–0.96
Sex† 0.37 1.55 0.59–4.08
Above-knee intervention† 0.91 1.06 0.41–2.75
Stents per leg† 0.16 1.46 0.86–2.47
Ejection fraction 40%† 0.56 1.13 0.31–4.07D
Significant covariate. †Other factors added 1 at a time, controlling for first 5 variables.
CI  confidence interval.vs. 6) (Fig. 5B). These observations have important impli-
ations for future CLI trials because outcomes must be nor-
alized according to entry Rutherford categories.
Unlike previous CLI studies, 90% of the PaRADISE
tudy patients were maintained on a regimen of life-long
ual antiplatelet agents, and nearly 75% received statins.
n comparison, only 66% of BASIL study patients
eceived aspirin and fewer than one-third received st-
tins. The rationale for dual antiplatelet agents was
redicated on extensive coronary DES data demonstrat-
ng improved stent patency with combined aspirin and
hienopyridines (18). Additionally, recent studies suggest
hat survival and limb salvage are favorably influenced
hen vascular patients are treated with thienopyridines
nd statins (19,20).
ationale for treating BTK CLI with DES. The limita-
ions of balloon PTA for BTK CLI are well documented.
he recent meta-analysis by Romiti et al. (4) found a 23%
ailure rate at 1 month and a 1-year primary patency of 58%
fter crural PTA. Kudo et al. (5) observed that only 25%
f tibial vessels were patent 3 years after PTA. To overcome
hese limitations, we postulated that tibial PTA with BMS
ight improve early outcomes (7). This approach was
redicated on the similarities between coronary and tibial
essels regarding histology, vessel diameter, and risk factors.
owever, analogous to coronary intervention, the late benefits
f BMS were partially mitigated by in-stent restenosis rates
etween 20% and 60% (18,19,21).
A number of small, single-center BTK-DES have been
eported. Siablis et al. (8) observed that after 6 months, 92%
f BTK DES were patent compared to 68% of BMS.
cheinert et al. (9) found the occlusion/binary restenosis
ates for provisional BTK BMS stenting were 17% and
9%, respectively, versus no events with the Cypher
Figure 6 The PaRADISE Trial Amputation-Free Survival
Kaplan-Meier amputation-free survival curve (combined death and major
amputation).ES. Similar favorable results have been reported by
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21) reviewed 18 BMS and DES studies and concluded
hat sirolimus-eluting stents appear to be superior to
MS or paclitaxel-eluting stents in terms of angiographic
nd clinical outcomes.
echnical and safety considerations. The PaRADISE
tudy is the first BTK DES trial to test a strategy of primary
nd not provisional (“bail-out”) stenting. Analogous to
ontemporary coronary intervention, we believed that pri-
ary stenting would translate into improved outcomes
econdary to less arterial trauma, need for fewer stents,
educed contrast load, shorter procedures, and fewer rein-
erventions. As noted in the BASIL trial, contemporary
TA was associated with a 20% 1-month failure rate
hereas early reintervention in PaRADISE was 2%.
Overlapping stents were placed in 35% of patients, with
engths ranging up to 96 mm. Despite treating more diffuse
isease, stent delivery was easy, and the presence of over-
apping stents did not predict subsequent stent failure or
mputation. When diffuse disease (96 mm) was encoun-
ered, PTA was used to treat the midvessel lesion while
eserving DES for inflow and intervening areas of prior total
cclusion. Preliminary observations suggest that placement
f a more proximal DES has a positive “wash-out” effect on
he downstream PTA site.
Although Taxus stents failed more frequently than
ypher stents, the number of events were too small to draw
rm conclusions. Siablis et al. (22) evaluated the efficacy of
aclitaxel DES in 32 limbs with CLI and observed that, at
 4 months, the restenosis and occlusion rates were 77%
nd 24%, respectively. The reason for these less favorable
utcomes is not clear, although these patients were treated
ith provisional stenting and dual platelet agents were
iscontinued after 6 months. Nevertheless, differences be-
ween the antiproliferative and thrombotic effects of siroli-
us versus paclitaxel cannot be discounted (23).
Mechanical stent deformation is a potential concern.
onsequently, we avoided stenting distal to the ankle,
here the tibial arteries lose their compartmental protec-
ion. Cypher stents placed in the distal popliteal or ostial
nterior tibial arteries were occasionally subject to strut
Comparison of Outcomes in the PaRADISE StudBASIL Study: Amputation-Free Survival and OverTable 6 Co arison of Outcomes in the PaRBASIL Study: Amputation-Free Surv
Outcome 1 Year (p Valu
Amputation-free survival
PaRADISE vs. BASIL PTA 10.9 5.0 (0.0
PaRADISE vs. BASIL surgery 13.9 5.0 (0.0
PaRADISE vs. PTA  surgery 12.4 4.5 (0.0
Overall survival
PaRADISE vs. BASIL PTA 5.0 4.3 (0.2
PaRADISE vs. BASIL surgery 9.0 4.4 (0.0
PaRADISE vs. PTA  surgery 6.9 3.9 (0.0
Positive values indicate higher survival in the PaRADISE study.
PTA  percutaneous transluminal angioplasty.isalignment and restenosis. We suspect that this may be recondary to out-of-plane biomechanical forces exerted by
he interosseous membrane and more mobile stented pop-
iteal artery. The issue of tibial stent crush was addressed by
arnabatidis et al. (24), who found a combined fracture/
ompression rate of 3.3% of 396 tibial stents evaluated.
owever, nearly all these events were associated with stents
laced below the ankle.
imitations of the PaRADISE study. The PaRADISE
tudy was a nonrandomized study designed to test proof of
rinciple that primary tibial stenting with DES was effective
nd safe. Although not ideal, the TASC II study and BASIL
tudy data are reasonable “first pass” comparators to benchmark
he outcomes of contemporary CLI therapies. Ultimately,
ndustry must sponsor randomized “primary” DES versus PTA
tudies to substantiate and refine these findings.
The PaRADISE study was a single-center and single-
perator trial, and thus the possibility of referral bias cannot
e discounted. Had the PaRADISE trial included a greater
umber of Rutherford 6 patients, the outcomes might have
een less dramatic. Nevertheless, the data support the safety
nd efficacy of BTK DES. From a technical standpoint, the
reatest interventional limitation was not sustaining tibial
atency but, rather, accessing the tibial vessels in the face of
hronically occluded femoral-popliteal arteries. In the fu-
ure, hybrid procedures, namely, femoral-popliteal bypass
ith adjunctive BTK DES, can be considered for these
hallenging patients.
Revascularization was not always as complete as desired
econdary to limits placed on the number of stents per leg.
ore than one-half of patients returning for repeat revas-
ularization required stenting in a different tibial vessel or at
site removed from the initial target. Whether multivessel
evascularization will improve salvage compared to the
urgical approach of establishing single-vessel flow needs
o be evaluated. Additionally, the merits of dedicated
ong versus overlapping DES, crush-resistant DES for
nprotected areas, and small-diameter stents need further
nvestigation.
Future studies will need to address the health economics
nd quality of life issues associated with a DES-centered
trategy. We anticipate that improved limb salvage should
susurvivalE Study Versus
nd Overall Survival
2 Years (p Value) 3 Years (p Value)
11.0 6.1 (0.07) 15.9 7.3 (0.03)
12.0 6.0 (0.05) 10.9 7.0 (0.12)
11.5 5.4 (0.03) 13.1 6.3 (0.04)
2.6 5.8 (0.65) 8.7 7.0 (0.22)
7.6 5.8 (0.19) 5.7 6.9 (0.41)
5.2 5.2 (0.32) 7.1 6.1 (0.24)y Verall SADIS
ival a
e)
3)
1)
1)
5)
4)
7)esult in significant savings secondary to reductions in
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April 13, 2010:1580–9 Preventing Leg Amputations With DESypass surgery, amputation, infections, graft surveillance,
nd shorter hospitalizations. Additionally, the benefits of
reserving independent living and avoiding custodial care
hould not be underestimated.
Finally, the PaRADISE study was not designed to
valuate angiographic restenosis. Nevertheless, restenosis
tself may not be a rate-limiting end point as long as tibial
atency is maintained long enough to permit tissue healing
nd resolution of symptoms. Future studies will need to
valuate the biologic response to BTK stenting with DES.
onclusions
reating BTK CLI with DES appears to be a safe and
ffective means of preventing major amputations and reliev-
ng symptoms. Procedural complications and revasculariza-
ions were low. Patients treated with DES have significantly
ewer major amputations and higher survival rates than
istoric controls. These data support a DES-first approach
hen treating infrapopliteal CLI. Based on the accumulat-
ng evidence, we propose industry-sponsored trials to reaf-
rm these findings and evaluate the health care economic
mpact of a DES-centered paradigm for treating CLI.
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